Literature DB >> 17007987

Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning.

Daniel Rochu1, Eric Chabrière, Patrick Masson.   

Abstract

The limited efficiency of medical countermeasures against poisoning by nerve agent justifies efforts to find new prophylactic means and new antidotes. The concept of bioscavengers has emerged as an alternative approach to pharmacological pre- and post-exposure treatments. Catalytic scavengers are enzymes displaying a turnover with OPs as substrates, allowing rapid and efficient protection using administration of small doses. Several reasons have endorsed human paraoxonase (PON1) to be a pertinent candidate as catalytic bioscavenger. The physiological function of PON1 has not yet been unambiguously identified. Considered as a promiscuous enzyme, PON1 appears to be primarily a lactonase and also displays an anti-atherogenic activity closely linked to its localization on HDL particles. A HDL-associated phosphate transporter termed human phosphate binding protein (HPBP) was found to be a partner of natural human PON. In the absence of its natural environment (or mimicry by detergents), human PON1 is unstable and tends to aggregate. Converging data indicate that both the activity and the stability of PON1 are dramatically dependent on the HDL component molecular environment, including HPBP. Therefore, biochemical and physiological characterization of PON1-HPBP complexes, the environment allowing retaining functional enzyme state(s), and the thermal and storage stability of PON1 are mandatory. Synergistic efforts on characterization of recombinant hybrid PON1 expressed in E. coli and natural human PON1 provide information for the future rational design of stable mutants of PON1-based catalytic scavengers to be used as safe and effective countermeasures to OP intoxication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17007987     DOI: 10.1016/j.tox.2006.08.037

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  23 in total

1.  Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  Protein Sci       Date:  2013-10-26       Impact factor: 6.725

2.  Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer.

Authors:  H Balci; H Genc; C Papila; G Can; B Papila; H Yanardag; H Uzun
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

3.  HI-6 assisted catalytic scavenging of VX by acetylcholinesterase choline binding site mutants.

Authors:  Nikolina Maček Hrvat; Suzana Žunec; Palmer Taylor; Zoran Radić; Zrinka Kovarik
Journal:  Chem Biol Interact       Date:  2016-04-12       Impact factor: 5.192

4.  Computational characterization of how the VX nerve agent binds human serum paraoxonase 1.

Authors:  Steven Z Fairchild; Matthew W Peterson; Adel Hamza; Chang-Guo Zhan; Douglas M Cerasoli; Wenling E Chang
Journal:  J Mol Model       Date:  2010-04-09       Impact factor: 1.810

Review 5.  Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead.

Authors:  A R Satvik Iyengar; Abhay H Pande
Journal:  Protein J       Date:  2016-12       Impact factor: 2.371

6.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

7.  Detoxification of Organophosphate Poisoning Using Nanoparticle Bioscavengers.

Authors:  Zhiqing Pang; Che-Ming J Hu; Ronnie H Fang; Brian T Luk; Weiwei Gao; Fei Wang; Erdembileg Chuluun; Pavimol Angsantikul; Soracha Thamphiwatana; Weiyue Lu; Xinguo Jiang; Liangfang Zhang
Journal:  ACS Nano       Date:  2015-06-08       Impact factor: 15.881

8.  IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier.

Authors:  Ruben J Boado; Yun Zhang; Yufeng Zhang; Yuntao Wang; William M Pardridge
Journal:  Mol Pharm       Date:  2008 Nov-Dec       Impact factor: 4.939

9.  Abundance of plasma antioxidant proteins confers tolerance to acute hypobaric hypoxia exposure.

Authors:  Gayatri Padhy; Niroj Kumar Sethy; Lilly Ganju; Kalpana Bhargava
Journal:  High Alt Med Biol       Date:  2013-09       Impact factor: 1.981

10.  Identification of Critical Paraoxonase 1 Residues Involved in High Density Lipoprotein Interaction.

Authors:  Xiaodong Gu; Ying Huang; Bruce S Levison; Gary Gerstenecker; Anthony J DiDonato; Leah B Hazen; Joonsue Lee; Valentin Gogonea; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2015-11-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.